PMX-30063, a drug being developed by PolyMedix for the treatment of acute care conditions, has shown potential as a topical treatment for oral mucositis in patients undergoing radiation and chemotherapy, according to research presented June 2 at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
The data summarized two preclinical studies in which PMX-30063 was administered to animals as a topical rinse three times daily in models of acute and fractionated radiation, the researchers noted. In each of the two controlled studies, the drug substantially reduced the peak mean mucositis scores and the duration of ulcerative mucositis by a statistically significant margin compared with vehicle-treated animals.
In both studies, no significant changes in weight gain or adverse clinical signs were detected in any of the animals in the PMX-30063 treatment groups.
